Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial

Hisham Mehanna*, Max Robinson, Andrew Hartley, Anthony Kong, Bernadette Foran, Tessa Fulton-Lieuw, Matthew Dalby, Pankaj Mistry, Mehmet Sen, Lorcan O'Toole, Hoda Al Booz, Karen Dyker, Rafael Moleron, Stephen Whitaker, Sinead Brennan, Audrey Cook, Matthew Griffin, Eleanor Aynsley, Martin Rolles, Emma De WintonAndrew Chan, Devraj Srinivasan, Ioanna Nixon, Joanne Grumett, C. René Leemans, Jan Buter, Julia Henderson, Kevin Harrington, Christopher McConkey, Alastair Gray, Janet Dunn, De-ESCALaTE HPV Trial Group, Laura Pettit (Contributor), Paul Nankivell (Contributor), Jennifer Bryant (Contributor), Neil Sharma (Contributor), Rachel Spruce (Contributor), Jill Brooks (Contributor)

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

286 Citations (Scopus)
236 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences